Tvardi Therapeutics (TVRD) Common Equity (2016 - 2025)
Tvardi Therapeutics' Common Equity history spans 13 years, with the latest figure at $20.9 million for Q4 2025.
- On a quarterly basis, Common Equity rose 122.98% to $20.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.9 million, a 122.98% increase, with the full-year FY2025 number at $20.9 million, up 122.98% from a year prior.
- Common Equity hit $20.9 million in Q4 2025 for Tvardi Therapeutics, down from $27.9 million in the prior quarter.
- Over the last five years, Common Equity for TVRD hit a ceiling of $230.5 million in Q1 2021 and a floor of -$100.6 million in Q1 2025.
- Historically, Common Equity has averaged $78.1 million across 5 years, with a median of $97.3 million in 2023.
- Biggest five-year swings in Common Equity: crashed 191.66% in 2024 and later surged 145.06% in 2025.
- Tracing TVRD's Common Equity over 5 years: stood at $227.5 million in 2021, then crashed by 30.21% to $158.8 million in 2022, then crashed by 139.08% to -$62.1 million in 2023, then plummeted by 46.85% to -$91.1 million in 2024, then soared by 122.98% to $20.9 million in 2025.
- Business Quant data shows Common Equity for TVRD at $20.9 million in Q4 2025, $27.9 million in Q3 2025, and $32.9 million in Q2 2025.